Cellular therapy of the corneal stroma: a new type of corneal surgery for keratoconus and corneal dystrophies.
Cellular therapy of the corneal stroma: a new type of corneal surgery for keratoconus and corneal dystrophies.
复制标题
DOI：
10.1186/s40662-018-0122-1
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Alió JL
中科院分区：
文献类型：
--
作者：
Alió Del Barrio JL;Alió JL
角膜基质的细胞治疗，无论是眼或眼外干细胞，已经获得了很多的兴趣，在过去的十年。来自不同研究小组的多篇出版物显示了其改善或减轻角膜瘢痕的能力，通过增强累积分子的催化作用改善代谢性疾病中的角膜透明度，在宿主基质内产生新的组织化胶原蛋白及其免疫抑制和免疫调节特性的潜在益处。自体眼外干细胞不需要健康的对侧眼睛，并且它们不涉及任何用于分离它们的眼科程序。间充质干细胞已被最广泛地检测，并且在体内和体外具有分化为功能性成体角膜细胞的最佳潜力。虽然胚胎干细胞由于伦理问题已经部分被放弃，但诱导多能干细胞（iPSC）的发现为未来的研究开辟了一个新的非常有前途的领域，因为它们是多能细胞，理论上能够分化成任何细胞类型，具有特殊的优势，它们是从成体分化细胞中获得的。已经以多种方式在体内实验性地测定了细胞递送到角膜基质中：有或没有载体的全身注射与局部注射。令人鼓舞的初步人类临床数据已经可用，尽管仍然非常有限，并且为了巩固这种新型治疗线的临床应用，需要进一步的研究。
Cellular therapy of the corneal stroma, with either ocular or extraocular stem cells, has been gaining a lot of interest over the last decade. Multiple publications from different research groups are showing its potential benefits in relation to its capacity to improve or alleviate corneal scars, improve corneal transparency in metabolic diseases by enhancing the catabolism of the accumulated molecules, generate new organized collagen within the host stroma, and its immunosuppressive and immunomodulatory properties. Autologous extraocular stem cells do not require a healthy contralateral eye and they do not involve any ophthalmic procedures for their isolation. Mesenchymal stem cells have been the most widely assayed and have the best potential to differentiate into functional adult keratocytes in vivo and in vitro. While embryonic stem cells have been partially abandoned due to ethical implications, the discovery of the induced pluripotent stem cells (iPSC) has opened a new and very promising field for future research as they are pluripotent cells with the capacity to theoretically differentiate into any cell type, with the special advantage that they are obtained from adult differentiated cells. Cellular delivery into the corneal stroma has been experimentally assayed in vivo in multiple ways: systemic versus local injections with or without a carrier. Encouraging preliminary human clinical data is already available although still very limited, and further research is necessary in order to consolidate the clinical applications of this novel therapeutic line.
登录
查看更多内容
影响因子：
14
作者：
Choi, Jin San;Williams, James K.;Soker, Shay
通讯作者：
Soker, Shay
影响因子：
5.2
作者：
Du, Yiqin;Carlson, Eric C.;Funderburgh, Martha L.;Birk, David E.;Pearlman, Eric;Guo, Naxin;Kao, Winston W. -Y.;Funderburgh, James L.
通讯作者：
Funderburgh, James L.
影响因子：
3.4
作者：
Alio del Barrio, Jorge L.;Chiesa, Massimo;De Miguel, Maria P.
通讯作者：
De Miguel, Maria P.
DOI：
10.3760/cma.j.issn.0412-4081.2016.03.009
发表时间：
2016-03-01
期刊：
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
影响因子：
--
作者：
Bai, H;Wang, L L;Huang, J X
通讯作者：
Huang, J X
影响因子：
5.2
作者：
Coulson-Thomas, Vivien Jane;Caterson, Bruce;Kao, Winston W-Y.
通讯作者：
Kao, Winston W-Y.